SCHEMBL14730707

SCHEMBL14730707

CC1(C)CC2(CCC2)c2c([nH]c3ccc(C(=O)O)cc23)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 2/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 1/20 0.42
THRB P10828 1/20 0.42
HPGD P15428 1/20 0.42
GSK3B P49841 2/20 0.42
CCNB2 O95067 1/20 0.42
CDK1 P06493 1/20 0.42
CCNB1 P14635 1/20 0.42
CCNB3 Q8WWL7 1/20 0.42
PPARG P37231 1/20 0.40
GSK3A P49840 1/20 0.39
CDK5 Q00535 1/20 0.39
CDK5R1 Q15078 1/20 0.39
KIF11 P52732 1/20 0.38
PARP1 P09874 3/20 0.37
APEX1 P27695 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14730786 0.88 CCNB2 (0.47) MAPKAPK2KDM4EALDH1A1HPGDGSK3B
SCHEMBL14730689 0.87 KDM4E (0.47) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14730704 0.82 KDR (0.43) MAPKAPK2FLT3
SCHEMBL14730691 0.81 GSK3B (0.40) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14730809 0.80 ALK (0.44) ALDH1A1KMT2AMAPTL3MBTL1POLB
SCHEMBL13248584 0.79 MAPKAPK2 (0.64) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL14730749 0.78 KDR (0.44) MAPKAPK2FLT3
SCHEMBL14730719 0.77 KDM4E (0.44) MAPKAPK2KDM4EALDH1A1THRBHPGD
SCHEMBL16248398 0.77 KIF11 (0.44) MAPKAPK2KDM4EALDH1A1GSK3BCCNB2
SCHEMBL14730855 0.76 MAPKAPK2 (0.49) MAPKAPK2KDM4EGSK3BCCNB2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-9340539-B2 Hepatitis C inhibitor compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-05-17 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
WO-2013026163-A1 HEPATITIS C INHIBITOR COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343077-A1 HEPATITIS C INHIBITOR COMPOUNDS HCCS, C1R, HAVCR2 MAPKAPK2 4574/4885KDM4E 4061/4885ALDH1A1 1605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.